Crispr Therapeutics (NASDAQ:CRSP) had its target price upped by Roth Capital from $65.00 to $100.00 in a research note issued to investors on Tuesday, November 19th, The Fly reports.
Several other research firms have also issued reports on CRSP. Goldman Sachs Group lifted their target price on shares of Crispr Therapeutics from $52.00 to $75.00 and gave the company a neutral rating in a report on Tuesday, November 19th. Chardan Capital restated a buy rating and issued a $72.50 target price on shares of Crispr Therapeutics in a research report on Monday, November 18th. Jefferies Financial Group started coverage on shares of Crispr Therapeutics in a research report on Thursday, August 1st. They issued a buy rating and a $64.00 price objective for the company. ValuEngine raised Crispr Therapeutics from a sell rating to a hold rating in a report on Friday, November 1st. Finally, William Blair upgraded shares of Crispr Therapeutics from a market perform rating to an outperform rating in a research note on Tuesday, November 19th. Two analysts have rated the stock with a sell rating, two have given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. Crispr Therapeutics currently has an average rating of Buy and a consensus target price of $69.54.
Shares of CRSP stock traded down $0.26 during mid-day trading on Tuesday, hitting $71.84. 699,314 shares of the stock traded hands, compared to its average volume of 701,470. The company’s 50-day simple moving average is $53.47 and its 200-day simple moving average is $47.06. Crispr Therapeutics has a twelve month low of $22.22 and a twelve month high of $74.00. The firm has a market cap of $3.95 billion, a price-to-earnings ratio of -20.88 and a beta of 3.30. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32.
Crispr Therapeutics (NASDAQ:CRSP) last released its earnings results on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. The company had revenue of $211.93 million for the quarter, compared to analysts’ expectations of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. Analysts forecast that Crispr Therapeutics will post 0.65 earnings per share for the current year.
In related news, President Rodger Novak sold 33,618 shares of the stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the sale, the president now directly owns 33,618 shares of the company’s stock, valued at $2,353,260. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Pablo J. Cagnoni sold 7,500 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $52.00, for a total value of $390,000.00. Following the completion of the transaction, the director now owns 7,500 shares in the company, valued at approximately $390,000. The disclosure for this sale can be found here. Insiders sold a total of 56,118 shares of company stock valued at $3,620,760 in the last ninety days. 21.40% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. NEXT Financial Group Inc boosted its holdings in shares of Crispr Therapeutics by 915.0% during the 3rd quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock valued at $25,000 after acquiring an additional 549 shares during the last quarter. Benjamin Edwards Inc. increased its holdings in Crispr Therapeutics by 96.4% in the second quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock valued at $26,000 after buying an additional 268 shares in the last quarter. Coastal Investment Advisors Inc. purchased a new position in Crispr Therapeutics in the 3rd quarter valued at $26,000. US Bancorp DE raised its position in Crispr Therapeutics by 553.7% in the second quarter. US Bancorp DE now owns 621 shares of the company’s stock valued at $29,000 after purchasing an additional 526 shares during the period. Finally, BSW Wealth Partners purchased a new position in Crispr Therapeutics in the 2nd quarter valued at approximately $39,000. 49.81% of the stock is currently owned by institutional investors and hedge funds.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Story: Why is the price-sales ratio important?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.